{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T06:56:29Z","timestamp":1781160989810,"version":"3.54.1"},"reference-count":138,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Carbapenem-resistant Enterobacterales (CRE) are a major therapeutic challenge because of limited treatment options and high mortality. Despite advances in resistance-targeted therapies and pharmacokinetic (PK) optimization, treatment failure remains common. This review examines how resistance mechanisms and antibiotic exposure at the infection site jointly influence therapeutic outcomes in CRE infections. A mechanistic synthesis of evidence on carbapenem PKs, bacterial resistance, and nanoparticle (NP)-based delivery systems was performed. Based on this analysis, we propose the Pre-Target Interception Model (PTIM), which describes treatment failure as the progressive loss of active antibiotic before reaching penicillin-binding proteins. Unlike conventional approaches that focus primarily on resistance determinants or drug delivery platforms, PTIM emphasizes the factors that limit effective antibiotic exposure within infected tissues. Within this framework, nanocarrier systems are assessed according to their ability to protect antibiotics, enhance tissue penetration, and improve retention under conditions of enzymatic degradation, membrane restriction, efflux activity, and biofilm-associated diffusion barriers. However, clinical translation remains limited by manufacturing challenges, variability in NP performance, and the lack of validation in CRE-specific settings. Future progress will require quantitative measurement of antibiotic exposure at infection sites, standardized evaluation of nanocarrier performance, and validation in clinically relevant models. PTIM provides a framework for the rational development of nanomedicines designed to improve antibiotic delivery in CRE infections.<\/jats:p>","DOI":"10.3390\/pharmaceutics18060717","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:50:58Z","timestamp":1781157058000},"page":"717","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pre-Target Interception Defines Carbapenem Failure in Carbapenem-Resistant Enterobacterales: A Mechanistic Framework for Spatiotemporal Drug Reprogramming"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1699-6263","authenticated-orcid":false,"given":"Eman","family":"Marzouk","sequence":"first","affiliation":[{"name":"Department of Public Health, College of Applied Medical Sciences, Qassim University, P.O. Box 6666, Buraydah 51452, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7726-9532","authenticated-orcid":false,"given":"Ayman","family":"Elbehiry","sequence":"additional","affiliation":[{"name":"Department of Public Health, College of Applied Medical Sciences, Qassim University, P.O. Box 6666, Buraydah 51452, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Chen, H.-Y., Jean, S.-S., Lee, Y.-L., Lu, M.-C., Ko, W.-C., Liu, P.-Y., and Hsueh, P.-R. (2021). Carbapenem-resistant Enterobacterales in long-term care facilities: A global and narrative review. Front. Cell. Infect. Microbiol., 11.","DOI":"10.3389\/fcimb.2021.601968"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Caliskan-Aydogan, O., and Alocilja, E.C. (2023). A review of carbapenem resistance in Enterobacterales and its detection techniques. Microorganisms, 11.","DOI":"10.3390\/microorganisms11061491"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1007\/s10096-021-04296-1","article-title":"Treatment for carbapenem-resistant Enterobacterales infections: Recent advances and future directions","volume":"40","author":"Tompkins","year":"2021","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13756-023-01323-y","article-title":"Clinical significance and burden of carbapenem-resistant Enterobacterales (CRE) colonization acquisition in hospitalized patients","volume":"12","author":"Hussien","year":"2023","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"ofy150","DOI":"10.1093\/ofid\/ofy150","article-title":"Association between carbapenem resistance and mortality among adult, hospitalized patients with serious infections due to Enterobacteriaceae: Results of a systematic literature review and meta-analysis","volume":"5","author":"Martin","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1017\/ice.2017.197","article-title":"Carbapenem resistance, initial antibiotic therapy, and mortality in Klebsiella pneumoniae bacteremia: A systematic review and meta-analysis","volume":"38","author":"Kohler","year":"2017","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_7","unstructured":"World Health Organization (WHO) (2024). WHO Bacterial Priority Pathogens List, 2024: Bacterial Pathogens of Public Health Importance, to Guide Research, Development and Strategies to Prevent and Control Antimicrobial Resistance, World Health Organization. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240093461."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1128\/AAC.00296-11","article-title":"Carbapenems: Past, present, and future","volume":"55","author":"Endimiani","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.15616\/BSL.2024.30.3.101","article-title":"Prevalence of Carbapenem-Resistant Enterobacterales and Their Diverse Resistance Mechanisms","volume":"30","author":"Kim","year":"2024","journal-title":"Biomed. Sci. Lett."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2217\/nnm-2023-0022","article-title":"Nanomedicine to overcome antimicrobial resistance: Challenges and prospects","volume":"18","author":"Zou","year":"2023","journal-title":"Nanomedicine"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nrd4333","article-title":"Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery","volume":"13","author":"Torchilin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/femsre\/fux010","article-title":"Molecular mechanisms of biofilm-based antibiotic resistance and tolerance in pathogenic bacteria","volume":"41","author":"Hall","year":"2017","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2017.09.015","article-title":"Nanoparticle-based local antimicrobial drug delivery","volume":"127","author":"Gao","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrmicro862","article-title":"Antimicrobial pharmacodynamics: Critical interactions of\u2019bug and drug\u2019","volume":"2","author":"Drusano","year":"2004","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1097\/CCM.0b013e3181961bff","article-title":"Pharmacokinetic issues for antibiotics in the critically ill patient","volume":"37","author":"Roberts","year":"2009","journal-title":"Crit. Care Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: A Position Paper# MH Abdul-Aziz et al","volume":"46","author":"Alffenaar","year":"2020","journal-title":"Intensive Care Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"115945","DOI":"10.1016\/j.diagmicrobio.2023.115945","article-title":"Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam activities against multidrug-resistant Enterobacterales from United States Medical Centers (2018\u20132022)","volume":"106","author":"Sader","year":"2023","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Bonnin, R.A., Bernabeu, S., Emeraud, C., Naas, T., Girlich, D., Jousset, A.B., and Dortet, L. (2023). In vitro activity of imipenem-relebactam, meropenem-vaborbactam, ceftazidime-avibactam and comparators on carbapenem-resistant non-carbapenemase-producing Enterobacterales. Antibiotics, 12.","DOI":"10.3390\/antibiotics12010102"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3934\/microbiol.2018.3.482","article-title":"An overview of the antimicrobial resistance mechanisms of bacteria","volume":"4","author":"Reygaert","year":"2018","journal-title":"AIMS Microbiol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Miftode, I.-L., Radu, V.D., Jigoranu, R.-A., Leca, D.-A., Prepeliuc, C.S., Pasare, M.A., Miftode, R.-S., Grigoriu, M.G., Par\u00e2ng\u0103, T.G., and Miftode, E.G. (2026). Novel Insights into Carbapenem Resistance: Mechanisms, Diagnostics, and Future Directions. Antibiotics, 15.","DOI":"10.3390\/antibiotics15030270"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Alvisi, G., Curtoni, A., Fonnesu, R., Piazza, A., Signoretto, C., Piccinini, G., Sassera, D., and Gaibani, P. (2025). Epidemiology and genetic traits of carbapenemase-producing enterobacterales: A global threat to human health. Antibiotics, 14.","DOI":"10.3390\/antibiotics14020141"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40121-020-00395-2","article-title":"Continuous evolution: Perspective on the epidemiology of carbapenemase resistance among Enterobacterales and other Gram-negative bacteria","volume":"10","author":"Hansen","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijantimicag.2012.08.010","article-title":"Underlying mechanisms of carbapenem resistance in extended-spectrum \u03b2-lactamase-producing Klebsiella pneumoniae and Escherichia coli isolates at a tertiary care centre in Lebanon: Role of OXA-48 and NDM-1 carbapenemases","volume":"41","author":"Baroud","year":"2013","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Aurilio, C., Sansone, P., Barbarisi, M., Pota, V., Giaccari, L.G., Coppolino, F., Barbarisi, A., Passavanti, M.B., and Pace, M.C. (2022). Mechanisms of action of carbapenem resistance. Antibiotics, 11.","DOI":"10.3390\/antibiotics11030421"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Zdarska, V., Arcari, G., Kolar, M., and Mlynarcik, P. (2026). Antibiotic Resistance in Klebsiella pneumoniae and Related Enterobacterales: Molecular Mechanisms, Mobile Elements, and Therapeutic Challenges. Antibiotics, 15.","DOI":"10.3390\/antibiotics15010037"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.2147\/IDR.S244357","article-title":"Evaluation of resistance mechanisms in carbapenem-resistant Enterobacteriaceae","volume":"3","author":"Alizadeh","year":"2020","journal-title":"Infect. Drug Resist."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Tristancho-Bar\u00f3, A., L\u00f3pez-Calleja, A.I., Milagro, A., Ariza, M., Vi\u00f1eta, V., Fortu\u00f1o, B., L\u00f3pez, C., Latorre-Mill\u00e1n, M., Clusa, L., and Badenas-Alzugaray, D. (2025). Mechanisms of cefiderocol resistance in carbapenemase-producing enterobacterales: Insights from comparative genomics. Antibiotics, 14.","DOI":"10.20944\/preprints202505.2477.v1"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"El Naggar, N.M., Shawky, R.M., Serry, F.M., and Emara, M. (2024). Investigating the relationship between carbapenemase production and biofilm formation in Klebsiella pneumoniae clinical isolates. BMC Res. Notes, 17.","DOI":"10.1186\/s13104-024-06708-9"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Belay, W.Y., Getachew, M., Tegegne, B.A., Teffera, Z.H., Dagne, A., Zeleke, T.K., Abebe, R.B., Gedif, A.A., Fenta, A., and Yirdaw, G. (2024). Mechanism of antibacterial resistance, strategies and next-generation antimicrobials to contain antimicrobial resistance: A review. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1444781"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s00203-025-04298-z","article-title":"Newly developed antibiotics against multidrug-resistant and carbapenem-resistant Gram-negative bacteria: Action and resistance mechanisms","volume":"207","year":"2025","journal-title":"Arch. Microbiol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Kato, T., Yagi, Y., Maruyama, T., and Hamada, Y. (2025). Pharmacokinetics\/Pharmacodynamics-Based Repositioning of Cefmetazole and Flomoxef in Extended-Spectrum \u03b2-Lactamase-Producing Enterobacterales Treatment: An Injectable Carbapenem-Sparing and Outpatient Strategy. Antibiotics, 14.","DOI":"10.3390\/antibiotics14080737"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.jiph.2021.10.020","article-title":"Antibiotic resistance in microbes: History, mechanisms, therapeutic strategies and future prospects","volume":"14","author":"Uddin","year":"2021","journal-title":"J. Infect. Public Health"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Huang, Z., Bian, X., Li, Y., Hu, J., Guo, B., Yang, X., Jin, Y., Zheng, S., Wang, X., and Gao, C. (2024). In vitro pharmacokinetics\/pharmacodynamics of FL058 (a novel beta-lactamase inhibitor) combined with meropenem against carbapenemase-producing Enterobacterales. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1282480"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Xu, W., Shang, L., Li, X., Yu, J., Shen, J., Li, Y., He, Q., Chen, L., Wang, D., and Wei, Y. (2026). Current progress in antibacterial agents for carbapenem-resistant enterobacterales. Front. Pharmacol., 17.","DOI":"10.3389\/fphar.2026.1796557"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"147","DOI":"10.4155\/bio.12.310","article-title":"Rapid detection of carbapenemase activity through monitoring ertapenem hydrolysis in Enterobacteriaceae with LC\u2013MS\/MS","volume":"5","author":"Peaper","year":"2013","journal-title":"Bioanalysis"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"a025247","DOI":"10.1101\/cshperspect.a025247","article-title":"\u03b2-Lactams and \u03b2-lactamase inhibitors: An overview","volume":"6","author":"Bush","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e01730-17","DOI":"10.1128\/AAC.01730-17","article-title":"A systematic review and meta-analyses of the clinical epidemiology of carbapenem-resistant Enterobacteriaceae","volume":"62","author":"Vos","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1128\/CMR.00117-14","article-title":"The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria","volume":"28","author":"Li","year":"2015","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Mancuso, G., De Gaetano, S., Midiri, A., Zummo, S., and Biondo, C. (2023). The challenge of overcoming antibiotic resistance in carbapenem-resistant gram-negative bacteria:\u201cAttack on Titan\u201d. Microorganisms, 11.","DOI":"10.20944\/preprints202307.0676.v1"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"100052","DOI":"10.1016\/j.temicr.2025.100052","article-title":"Nanomaterials Against Antimicrobial Resistance and Beyond: Toward Mitigating Bacterial Resuscitation","volume":"2","author":"Thakur","year":"2025","journal-title":"Total Environ. Microbiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13099-024-00665-1","article-title":"Clonal and horizontal transmission of carbapenem-resistant Enterobacterales strains and genes via flies","volume":"16","author":"Xu","year":"2024","journal-title":"Gut Pathog."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e0154025","DOI":"10.1128\/mbio.01540-25","article-title":"The carbapenem inoculum effect provides insights into the molecular mechanisms underlying carbapenem resistance in the Enterobacterales","volume":"16","author":"Cartagena","year":"2025","journal-title":"mBio"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ijpharm.2009.11.033","article-title":"Liposomes as delivery systems for antibiotics","volume":"387","year":"2010","journal-title":"Int. J. Pharm."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: From concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Ferraz, M.P. (2024). Advanced nanotechnological approaches for biofilm prevention and control. Appl. Sci., 14.","DOI":"10.3390\/app14188137"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Sercombe, L., Veerati, T., Moheimani, F., Wu, S.Y., Sood, A.K., and Hua, S. (2015). Advances and challenges of liposome assisted drug delivery. Front. Pharmacol., 6.","DOI":"10.3389\/fphar.2015.00286"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.addr.2014.02.002","article-title":"Delivery of antibiotics with polymeric particles","volume":"78","author":"Xiong","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/jps.24298","article-title":"Nanoengineered drug delivery systems for enhancing antibiotic therapy","volume":"104","author":"Kalhapure","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.7150\/thno.82790","article-title":"Nanoparticle formulations for therapeutic delivery, pathogen imaging and theranostic applications in bacterial infections","volume":"13","author":"Jiang","year":"2023","journal-title":"Theranostics"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.carbpol.2017.07.030","article-title":"Ultrahigh antibacterial efficacy of meropenem-loaded chitosan nanoparticles in a septic animal model","volume":"174","author":"Abdelkader","year":"2017","journal-title":"Carbohydr. Polym."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12951-017-0262-9","article-title":"Imipenem\/cilastatin encapsulated polymeric nanoparticles for destroying carbapenem-resistant bacterial isolates","volume":"15","author":"Shaaban","year":"2017","journal-title":"J. Nanobiotechnol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"37708","DOI":"10.1038\/s41598-025-21606-1","article-title":"Nanotechnology Meets superbugs: Biocompatible polymeric nanoparticles combat MDR Klebsiella pneumoniae via gene suppression and biofilm Inhibition","volume":"15","author":"Ebrahimi","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1208\/s12249-014-0177-9","article-title":"Nanomedicine scale-up technologies: Feasibilities and challenges","volume":"15","author":"Paliwal","year":"2014","journal-title":"AAPS PharmSciTech"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Hua, S., De Matos, M.B., Metselaar, J.M., and Storm, G. (2018). Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: Pathways for translational development and commercialization. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.00790"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s11671-025-04244-4","article-title":"Nanomedicine approaches to enhance the effectiveness of meropenem: A strategy to tackle antimicrobial resistance","volume":"20","author":"Mengesha","year":"2025","journal-title":"Discov. Nano"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Nazari, M., and Hosseini, S.M. (2025). Evaluation of antibacterial and antibiofilm efficacy of gentamicin-loaded solid lipid nanoparticles (GM-SLNs) against Acinetobacter baumannii infections. BMC Chem., 19.","DOI":"10.1186\/s13065-025-01626-8"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Nemattalab, M., Rohani, M., Evazalipour, M., and Hesari, Z. (2022). Formulation of Cinnamon (Cinnamomum verum) oil loaded solid lipid nanoparticles and evaluation of its antibacterial activity against Multi-drug Resistant Escherichia coli. BMC Complement. Med. Ther., 22.","DOI":"10.1186\/s12906-022-03775-y"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1039\/C7CS00748E","article-title":"Combatting antibiotic-resistant bacteria using nanomaterials","volume":"48","author":"Gupta","year":"2019","journal-title":"Chem. Soc. Rev."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Barani, M., Zeeshan, M., Kalantar-Neyestanaki, D., Farooq, M.A., Rahdar, A., Jha, N.K., Sargazi, S., Gupta, P.K., and Thakur, V.K. (2021). Nanomaterials in the management of gram-negative bacterial infections. Nanomaterials, 11, Correction in Nanomaterials\u00a02026, 16, 641.","DOI":"10.3390\/nano16110641"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Gondal, A.J., Choudhry, N., Bukhari, H., Rizvi, Z., and Yasmin, N. (2022). Characterization of genomic diversity among carbapenem-resistant Escherichia coli clinical isolates and antibacterial efficacy of silver nanoparticles from Pakistan. Microorganisms, 10.","DOI":"10.3390\/microorganisms10112283"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s00284-026-04747-y","article-title":"Biogenic Silver Nanoparticles: An Antibacterial and Antibiofilm Approach to Control Carbapenem-Resistant Klebsiella pneumoniae","volume":"83","author":"Wozeak","year":"2026","journal-title":"Curr. Microbiol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Damasco, J.A., Ravi, S., Perez, J.D., Hagaman, D.E., and Melancon, M.P. (2020). Understanding nanoparticle toxicity to direct a safe-by-design approach in cancer nanomedicine. Nanomaterials, 10.","DOI":"10.3390\/nano10112186"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s42452-025-06601-5","article-title":"Magnetic nanoparticles as a promising antimicrobial agent for combating multidrug resistant bacteria: A review","volume":"7","author":"Orlandini","year":"2025","journal-title":"Discov. Appl. Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1039\/C7NH00167C","article-title":"A programmable lipid-polymer hybrid nanoparticle system for localized, sustained antibiotic delivery to Gram-positive and Gram-negative bacterial biofilms","volume":"3","author":"Baek","year":"2018","journal-title":"Nanoscale Horiz."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2304397","DOI":"10.1002\/advs.202304397","article-title":"Liposomal antibiotic booster potentiates carbapenems for combating NDMs-producing Escherichia coli","volume":"11","author":"Wu","year":"2024","journal-title":"Adv. Sci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"107268","DOI":"10.1016\/j.ijantimicag.2024.107268","article-title":"Development of an effective meropenem\/KPC-2 inhibitor combination to combat infections caused by carbapenem-resistant Klebsiella pneumoniae","volume":"64","author":"Tang","year":"2024","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"13039","DOI":"10.2147\/IJN.S554821","article-title":"Bridging the gap: The role of advanced formulation strategies in the clinical translation of nanoparticle-based drug delivery systems","volume":"20","author":"Herdiana","year":"2025","journal-title":"Int. J. Nanomed."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41551-017-0187-5","article-title":"Antibiotic-loaded nanoparticles targeted to the site of infection enhance antibacterial efficacy","volume":"2","author":"Hussain","year":"2018","journal-title":"Nat. Biomed. Eng."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"6278","DOI":"10.1039\/D3NA00530E","article-title":"Recent advances in nanoantibiotics against multidrug-resistant bacteria","volume":"5","author":"Li","year":"2023","journal-title":"Nanoscale Adv."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.cmi.2014.10.024","article-title":"ESCMID guideline for the diagnosis and treatment of biofilm infections 2014","volume":"21","author":"Bjarnsholt","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"AlQurashi, D.M., AlQurashi, T.F., Alam, R.I., Shaikh, S., and Tarkistani, M.A.M. (2025). Advanced nanoparticles in combating antibiotic resistance: Current innovations and future directions. J. Nanotheranostics, 6.","DOI":"10.3390\/jnt6020009"},{"key":"ref_73","unstructured":"Radovic-Moreno, A.F. (2013). Bacteria-Targeting Nanoparticles for Managing Infections. [Ph.D. Thesis, Massachusetts Institute of Technology]."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"40","DOI":"10.62063\/ecb-61","article-title":"Nanosomes carrying mycosynthesized silver nanoparticles as a drug delivery tool against MDR Salmonella typhi BTCB170","volume":"4","author":"Iqtedar","year":"2025","journal-title":"Eur. Chem. Biotechnol. J."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Amini, M.S., Baseri Salehi, M., and Bahador, N. (2024). Evaluating the antibacterial effect of meropenem-loaded chitosan\/sodium tripolyphosphate (TPP) nanoparticles on Acinetobacter baumannii isolated from hospitalized patients. BMC Infect. Dis., 24.","DOI":"10.1186\/s12879-024-09522-7"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijpharm.2017.04.019","article-title":"Formulation of carbapenems loaded gold nanoparticles to combat multi-antibiotic bacterial resistance: In vitro antibacterial study","volume":"525","author":"Shaker","year":"2017","journal-title":"Int. J. Pharm."},{"key":"ref_78","unstructured":"Wilson, C.E. (2024). Development and Evaluation of Meropenem Encapsulated Nanostructured Lipid Carriers as an Antimicrobial Treatment of Pseudomonas aeruginosa. [Master\u2019s Thesis, School of Pharmacy and Biomedical Science, University of Central Lancashire]."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1208\/s12249-016-0675-z","article-title":"Preparation and optimization of meropenem-loaded solid lipid nanoparticles: In vitro evaluation and molecular modeling","volume":"18","author":"Mhango","year":"2017","journal-title":"AAPS PharmSciTech"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"9681","DOI":"10.48048\/tis.2025.9681","article-title":"Comparative Effectiveness of Single, Dual, and Multi-Antibiotic Therapies in Managing Carbapenem-Resistant Enterobacterales: A Systematic Review and Meta-Analysis on Survival Rates","volume":"22","author":"Suswati","year":"2025","journal-title":"Trends Sci."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11274-024-03894-3","article-title":"The impact and safety of encapsulated nanomaterials as a new alternative against carbapenem resistant bacteria. A systematic review","volume":"40","author":"Abdallah","year":"2024","journal-title":"World J. Microbiol. Biotechnol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"9654","DOI":"10.3390\/ijms16059654","article-title":"Structural basis for carbapenem-hydrolyzing mechanisms of carbapenemases conferring antibiotic resistance","volume":"16","author":"Jeon","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"13608","DOI":"10.1038\/s41598-019-49264-0","article-title":"Mechanistic insights into \u03b2-lactamase-catalysed carbapenem degradation through product characterisation","volume":"9","author":"Lohans","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"42460","DOI":"10.1039\/D5RA04206B","article-title":"Nanoparticle-mediated approaches to combat antibiotic resistance: A comprehensive review on current progress, mechanisms, and future perspectives","volume":"15","author":"Hayat","year":"2025","journal-title":"RSC Adv."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Modi, S.K., Gaur, S., Sengupta, M., and Singh, M.S. (2023). Mechanistic insights into nanoparticle surface-bacterial membrane interactions in overcoming antibiotic resistance. Front. Microbiol., 14.","DOI":"10.3389\/fmicb.2023.1135579"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Elbehiry, A., and Abalkhail, A. (2025). Antimicrobial nanoparticles against superbugs: Mechanistic insights, biomedical applications, and translational frontiers. Pharmaceuticals, 18.","DOI":"10.3390\/ph18081195"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"102381","DOI":"10.1016\/j.mtbio.2025.102381","article-title":"Combating Gram-negative infections: The role of antimicrobial peptides and nanotechnology in overcoming antibiotic resistance","volume":"35","author":"Canales","year":"2025","journal-title":"Mater. Today Bio"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrmicro.2016.94","article-title":"Biofilms: An emergent form of bacterial life","volume":"14","author":"Flemming","year":"2016","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"ovae136","DOI":"10.1093\/lambio\/ovae136","article-title":"A combined therapy of meropenem\u2013ZnO nanoparticles efficiently eliminates carbapenem-resistant Klebsiella pneumoniae biofilms, with reduced nephrotoxicity (in vitro)","volume":"77","author":"Mohamed","year":"2024","journal-title":"Lett. Appl. Microbiol."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Saffari Natanzi, A., Poudineh, M., Karimi, E., Khaledi, A., and Haddad Kashani, H. (2025). Innovative approaches to combat antibiotic resistance: Integrating CRISPR\/Cas9 and nanoparticles against biofilm-driven infections. BMC Med., 23.","DOI":"10.1186\/s12916-025-04323-4"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Elashkar, E., Alfaraj, R., El-Borady, O.M., Amer, M.M., Algammal, A.M., and El-Demerdash, A.S. (2025). Novel silver nanoparticle-based biomaterials for combating Klebsiella pneumoniae biofilms. Front. Microbiol., 15.","DOI":"10.3389\/fmicb.2024.1507274"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Mouzakis, A., Panagopoulos, P., Papazoglou, D., and Petrakis, V. (2025). A comprehensive review of nanoparticles in the fight against antimicrobial resistance. Pathogens, 14.","DOI":"10.3390\/pathogens14111090"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Elbehiry, A., and Alajaji, A.I. (2026). Next-Generation Strategies for Controlling Foodborne Pathogens: Precision Antimicrobials, Biofilm Disruption, and Emerging Molecular Interventions. Foods, 15.","DOI":"10.3390\/foods15020194"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"7811","DOI":"10.2147\/IJN.S515798","article-title":"Daidzein-Decorated Gold Nanoparticles as a Novel Antimicrobial Strategy Against Carbapenem-Resistant Enterobacteriaceae","volume":"20","author":"Pan","year":"2025","journal-title":"Int. J. Nanomed."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Angeles Flores, G., Cusumano, G., Venanzoni, R., and Angelini, P. (2025). Advancements in antibacterial therapy: Feature papers. Microorganisms, 13.","DOI":"10.3390\/microorganisms13030557"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.addr.2013.07.011","article-title":"Nanotechnology as a therapeutic tool to combat microbial resistance","volume":"65","author":"Pelgrift","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jconrel.2011.07.002","article-title":"\u201cNanoantibiotics\u201d: A new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era","volume":"156","author":"Huh","year":"2011","journal-title":"J. Control. Release"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","article-title":"Individualised antibiotic dosing for patients who are critically ill: Challenges and potential solutions","volume":"14","author":"Roberts","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"ref_99","first-page":"277","article-title":"The antibiotic resistance crisis: Part 1: Causes and threats","volume":"40","author":"Ventola","year":"2015","journal-title":"Pharm. Ther."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2174\/092986710790416290","article-title":"Development of nanoparticles for antimicrobial drug delivery","volume":"17","author":"Zhang","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Ly, P.-D., Ly, K.-N., Phan, H.-L., Nguyen, H.H., Duong, V.-A., and Nguyen, H.V. (2024). Recent advances in surface decoration of nanoparticles in drug delivery. Front. Nanotechnol., 6.","DOI":"10.3389\/fnano.2024.1456939"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s43939-025-00489-z","article-title":"Biocompatible nanoparticles in medicine: From design to clinical translation","volume":"6","author":"Ellakwa","year":"2025","journal-title":"Discov. Mater."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"100117","DOI":"10.1016\/j.pscia.2026.100117","article-title":"Toxicity of nanostructures in drug delivery applications","volume":"4","author":"Edo","year":"2026","journal-title":"Pharm. Sci. Adv."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.tips.2022.05.001","article-title":"Nanomedicine: Controlling nanoparticle clearance for translational success","volume":"43","author":"Zhu","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"10642","DOI":"10.1021\/acs.est.5b01841","article-title":"Lipopolysaccharide density and structure govern the extent and distance of nanoparticle interaction with actual and model bacterial outer membranes","volume":"49","author":"Jacobson","year":"2015","journal-title":"Environ. Sci. Technol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cis.2017.07.029","article-title":"Membrane interactions and antimicrobial effects of inorganic nanoparticles","volume":"248","author":"Malmsten","year":"2017","journal-title":"Adv. Colloid Interface Sci."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"24888","DOI":"10.1039\/C9RA02082A","article-title":"Oxidative stress generated at nickel oxide nanoparticle interface results in bacterial membrane damage leading to cell death","volume":"9","author":"Behera","year":"2019","journal-title":"RSC Adv."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.arabjc.2015.08.008","article-title":"Green synthesized silver nanoparticles destroy multidrug resistant bacteria via reactive oxygen species mediated membrane damage","volume":"10","author":"Das","year":"2017","journal-title":"Arab. J. Chem."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12951-021-01203-w","article-title":"Acute exposure to gold nanoparticles aggravates lipopolysaccharide-induced liver injury by amplifying apoptosis via ROS-mediated macrophage-hepatocyte crosstalk","volume":"20","author":"Yang","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Malik, S., Muhammad, K., and Waheed, Y. (2023). Emerging applications of nanotechnology in healthcare and medicine. Molecules, 28.","DOI":"10.3390\/molecules28186624"},{"key":"ref_111","first-page":"30573","article-title":"Advances in nanomaterials for precision drug delivery: Insights into pharmacokinetics and toxicity","volume":"15","author":"Tripathi","year":"2024","journal-title":"BioImpacts"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1039\/D5PM00179J","article-title":"Advancements in nano-based drug delivery systems for therapeutics: A comprehensive review","volume":"3","author":"John","year":"2025","journal-title":"RSC Pharm."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2502315","DOI":"10.1002\/smll.202502315","article-title":"Nanoparticle therapeutics in clinical perspective: Classification, marketed products, and regulatory landscape","volume":"21","author":"Desai","year":"2025","journal-title":"Small"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"100083","DOI":"10.1016\/j.ntm.2025.100083","article-title":"Nanoparticles for drug delivery: Insight into in vitro and in vivo drug release from nanomedicines","volume":"4","author":"Ewii","year":"2025","journal-title":"Nano TransMed"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41467-018-03705-y","article-title":"Progress and challenges towards targeted delivery of cancer therapeutics","volume":"9","author":"Rosenblum","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Zhu, L. (2021). Stimuli-Responsive Nanomedicine, CRC Press.","DOI":"10.1201\/9780429295294"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.1038\/s41467-024-48838-5","article-title":"Rediscovery of mononuclear phagocyte system blockade for nanoparticle drug delivery","volume":"15","author":"Zelepukin","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"20220045","DOI":"10.1002\/EXP.20220045","article-title":"Advanced strategies to evade the mononuclear phagocyte system clearance of nanomaterials","volume":"3","author":"Lu","year":"2023","journal-title":"Exploration"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2174\/1573403X10666140914160554","article-title":"Nanoparticles and the mononuclear phagocyte system: Pharmacokinetics and applications for inflammatory diseases","volume":"10","author":"Song","year":"2014","journal-title":"Curr. Rheumatol. Rev."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"26269","DOI":"10.1038\/srep26269","article-title":"Surface modification of nanoparticles enables selective evasion of phagocytic clearance by distinct macrophage phenotypes","volume":"6","author":"Qie","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nnano.2012.237","article-title":"Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface","volume":"8","author":"Salvati","year":"2013","journal-title":"Nat. Nanotechnol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","article-title":"PLGA-based nanoparticles: An overview of biomedical applications","volume":"161","author":"Danhier","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/polym3031377","article-title":"Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier","volume":"3","author":"Makadia","year":"2011","journal-title":"Polymers"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"4799","DOI":"10.1021\/ja312221g","article-title":"Multifunctional mesoporous silica-coated graphene nanosheet used for chemo-photothermal synergistic targeted therapy of glioma","volume":"135","author":"Wang","year":"2013","journal-title":"J. Am. Chem. Soc."},{"key":"ref_125","first-page":"e03101","article-title":"Advances in Nanoparticles as Drug Delivery Systems: A Review","volume":"30","author":"Ayobami","year":"2025","journal-title":"Sci. Afr."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"e10143","DOI":"10.1002\/btm2.10143","article-title":"Nanoparticles in the clinic: An update","volume":"4","author":"Anselmo","year":"2019","journal-title":"Bioeng. Transl. Med."},{"key":"ref_127","first-page":"742","article-title":"Progress in nanomedicine: Approved and investigational nanodrugs","volume":"42","author":"Ventola","year":"2017","journal-title":"Pharm. Ther."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"e70210","DOI":"10.1002\/mbo3.70210","article-title":"Nanomedicine Strategies Against Biofilm-Associated Infections: Advances, Challenges, and Translational Barriers","volume":"15","author":"Farah","year":"2026","journal-title":"MicrobiologyOpen"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"5605","DOI":"10.1039\/D4NR04774E","article-title":"Nanomaterial-enabled anti-biofilm strategies: New opportunities for treatment of bacterial infections","volume":"17","author":"Xie","year":"2025","journal-title":"Nanoscale"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2544683","DOI":"10.1080\/10717544.2025.2544683","article-title":"Inhalable nanoparticle-based delivery systems for the treatment of pulmonary infections: Status quo and barrier-overcoming strategies","volume":"32","author":"Gao","year":"2025","journal-title":"Drug Deliv."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1021\/mp800049w","article-title":"Pharmacokinetics and biodistribution of nanoparticles","volume":"5","author":"Li","year":"2008","journal-title":"Mol. Pharm."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Halwani, A.A. (2022). Development of pharmaceutical nanomedicines: From the bench to the market. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14010106"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"M\u00fclhopt, S., Diabat\u00e9, S., Dilger, M., Adelhelm, C., Anderlohr, C., Bergfeldt, T., G\u00f3mez de la Torre, J., Jiang, Y., Valsami-Jones, E., and Langevin, D. (2018). Characterization of nanoparticle batch-to-batch variability. Nanomaterials, 8.","DOI":"10.3390\/nano8050311"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"100635","DOI":"10.1016\/j.rsurfi.2025.100635","article-title":"A review on multifunctional applications of nanoparticles: Analyzing their multi-physical properties","volume":"21","author":"Abdullah","year":"2025","journal-title":"Results Surf. Interfaces"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Sharmile, N., Chowdhury, R.R., and Desai, S. (2025). A comprehensive review of quality control and reliability research in micro\u2013nano technology. Technologies, 13.","DOI":"10.3390\/technologies13030094"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2217\/nnm-2017-0039","article-title":"Challenges associated and approaches for successful translation of nanomedicines into commercial products","volume":"12","author":"Agrahari","year":"2017","journal-title":"Nanomedicine"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"115862","DOI":"10.1016\/j.addr.2026.115862","article-title":"Towards clinical translation of nanomedicines: Formulation scale-up and large animal models","volume":"234","author":"Kelly","year":"2026","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"12406","DOI":"10.1038\/ncomms12406","article-title":"Structural basis of metallo-\u03b2-lactamase, serine-\u03b2-lactamase and penicillin-binding protein inhibition by cyclic boronates","volume":"7","author":"Brem","year":"2016","journal-title":"Nat. Commun."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/6\/717\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T06:00:28Z","timestamp":1781157628000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/6\/717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":138,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["pharmaceutics18060717"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18060717","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]}}}